Randomized, Open-label (Double Blind Among Rivaroxaban Groups in the Initial 3 Weeks), Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism.

Trial Profile

Randomized, Open-label (Double Blind Among Rivaroxaban Groups in the Initial 3 Weeks), Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Heparin; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms J-EINSTEIN DVT
  • Sponsors Bayer
  • Most Recent Events

    • 25 Sep 2015 According to a Bayer media release, based on data from this and J-EINSTEIN PE trial, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved rivaroxaban for the treatment and secondary prevention of pulmonary thromboembolism and deep vein thrombosis
    • 09 Jan 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 26 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top